11 Potential Biotech Buy Out Targets

Will one of these companies get bought out? Biotech are is blazing sector right now, and we identified a few to keep an eye on.The following firms either have potential blockbusters in the pipeline or unique niches that make them attractive buyout candidates. As always, use this list as a starting point for your own research and due dilligence. One we particularly think is interesting is Celldex Therapeutics Inc. (CLDX):Celldex is a biopharmaceutical company based out of New Jersey, and it utilizes its Precision Targeted Immunotherapy platform to develop pipeline candidates to target cancer and other difficult-to-treat diseases. As far back as 2007, Celldex was considered the “next big thing” in biotechs with promising results in early trials for lead drug candidate CDX-110.

The drug, now named Rindopepimut, has reached Phase III trials after showing great results in tackling brain cancer in Phase II. Survival increased to 26 months vs. the 15 month average for patients on drug Temodar. Temodar currently earns about $1 billion a year in revenue, meaning Celldex and Rindopepimut have big potential. Celldex trades at $4.10.

We could also see Alexion Pharmaceuticals Inc. (ALXN) getting bought out. Alexion focuses on the development of drugs for the treatment of life-threatening diseases, and currently has one product on the market, Soliris. Soliris treats paroxysmal nocturnal hemoglobinura, a genetic disease that destroys red blood cells, and causes half of those suffering from it to die within 15 years.To continue reading, click here.